Current controversies in early-stage melanoma: Questions on management and surveillance

Marki E. Klapperich, Glen M. Bowen, Douglas Grossman

Research output: Contribution to journalReview article

Abstract

There are a number of controversies and uncertainties relating to the management and surveillance of patients with early-stage, localized (ie, stage 0, I, and II) cutaneous melanoma. While tumor stage is a critical predictor of clinical outcome and guides treatment, accurate determination of stage may be affected by the biopsy technique used and the method of sectioning before histologic review. A new molecular prognostic test is available but has not been formally incorporated into staging or treatment guidelines. There are no randomized controlled clinical trials to support guidelines for surveillance following the treatment of early-stage melanoma. In the second article in this continuing medical education series, we review the controversies and uncertainties relating to these issues. The questions we address are controversial because they speak to clinical scenarios for which there are no evidence-based guidelines or randomized clinical trials with the consequence of considerable variability in clinical practice. Our goal is to provide the clinician with up-to-date contextual knowledge to appreciate the multiple sides of each controversy and to suggest pathways to resolution.

LanguageEnglish (US)
Pages15-25
Number of pages11
JournalJournal of the American Academy of Dermatology
Volume80
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Melanoma
Guidelines
Uncertainty
Randomized Controlled Trials
Continuing Medical Education
Biopsy
Skin
Therapeutics
Neoplasms

Keywords

  • imaging
  • melanoma
  • staging
  • surveillance
  • transection

ASJC Scopus subject areas

  • Dermatology

Cite this

Current controversies in early-stage melanoma : Questions on management and surveillance. / Klapperich, Marki E.; Bowen, Glen M.; Grossman, Douglas.

In: Journal of the American Academy of Dermatology, Vol. 80, No. 1, 01.01.2019, p. 15-25.

Research output: Contribution to journalReview article

@article{7a76c8c136564726a9b20ca2679b9aa6,
title = "Current controversies in early-stage melanoma: Questions on management and surveillance",
abstract = "There are a number of controversies and uncertainties relating to the management and surveillance of patients with early-stage, localized (ie, stage 0, I, and II) cutaneous melanoma. While tumor stage is a critical predictor of clinical outcome and guides treatment, accurate determination of stage may be affected by the biopsy technique used and the method of sectioning before histologic review. A new molecular prognostic test is available but has not been formally incorporated into staging or treatment guidelines. There are no randomized controlled clinical trials to support guidelines for surveillance following the treatment of early-stage melanoma. In the second article in this continuing medical education series, we review the controversies and uncertainties relating to these issues. The questions we address are controversial because they speak to clinical scenarios for which there are no evidence-based guidelines or randomized clinical trials with the consequence of considerable variability in clinical practice. Our goal is to provide the clinician with up-to-date contextual knowledge to appreciate the multiple sides of each controversy and to suggest pathways to resolution.",
keywords = "imaging, melanoma, staging, surveillance, transection",
author = "Klapperich, {Marki E.} and Bowen, {Glen M.} and Douglas Grossman",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jaad.2018.03.054",
language = "English (US)",
volume = "80",
pages = "15--25",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Current controversies in early-stage melanoma

T2 - Journal of the American Academy of Dermatology

AU - Klapperich, Marki E.

AU - Bowen, Glen M.

AU - Grossman, Douglas

PY - 2019/1/1

Y1 - 2019/1/1

N2 - There are a number of controversies and uncertainties relating to the management and surveillance of patients with early-stage, localized (ie, stage 0, I, and II) cutaneous melanoma. While tumor stage is a critical predictor of clinical outcome and guides treatment, accurate determination of stage may be affected by the biopsy technique used and the method of sectioning before histologic review. A new molecular prognostic test is available but has not been formally incorporated into staging or treatment guidelines. There are no randomized controlled clinical trials to support guidelines for surveillance following the treatment of early-stage melanoma. In the second article in this continuing medical education series, we review the controversies and uncertainties relating to these issues. The questions we address are controversial because they speak to clinical scenarios for which there are no evidence-based guidelines or randomized clinical trials with the consequence of considerable variability in clinical practice. Our goal is to provide the clinician with up-to-date contextual knowledge to appreciate the multiple sides of each controversy and to suggest pathways to resolution.

AB - There are a number of controversies and uncertainties relating to the management and surveillance of patients with early-stage, localized (ie, stage 0, I, and II) cutaneous melanoma. While tumor stage is a critical predictor of clinical outcome and guides treatment, accurate determination of stage may be affected by the biopsy technique used and the method of sectioning before histologic review. A new molecular prognostic test is available but has not been formally incorporated into staging or treatment guidelines. There are no randomized controlled clinical trials to support guidelines for surveillance following the treatment of early-stage melanoma. In the second article in this continuing medical education series, we review the controversies and uncertainties relating to these issues. The questions we address are controversial because they speak to clinical scenarios for which there are no evidence-based guidelines or randomized clinical trials with the consequence of considerable variability in clinical practice. Our goal is to provide the clinician with up-to-date contextual knowledge to appreciate the multiple sides of each controversy and to suggest pathways to resolution.

KW - imaging

KW - melanoma

KW - staging

KW - surveillance

KW - transection

UR - http://www.scopus.com/inward/record.url?scp=85058152084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058152084&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2018.03.054

DO - 10.1016/j.jaad.2018.03.054

M3 - Review article

VL - 80

SP - 15

EP - 25

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 1

ER -